Together, these data demonstrate LAMC2 as an oncogenic player in iCCA by promoting EGFR translation and an indicator to identify iCCA patients who may benefit from available EGFR‐targeted TKIs therapies. This evidence concerns the gene LAMC2 and infantile convulsions and choreoathetosis.